On June 24, 2021, "Taurus elite® transcatheter aortic valve system"of Peijia Medical Technology Co., Ltd has been approved by NMPA, registration Certificate No: National Device Registration Approval No.20213130464, which indicates that China's transcatheter aortic valve replacement (TAVR) will fully enter the "recyclable era".
LINKS clinical team is responsible for the whole process of the overall clinical trial design, organization and implementation of the project, which lasted 18.5 months - starting,enrollment, completing the follow-up and obtaining the production license, the clinical report reviewed by NMPA in the epidemic situation. TaurusElite ®，a golden bull born in the year of the ox will definitely be "bullish"! Best wishes to Taurus elite ® that bring happiness and vitality to more patients with aortic stenosis. Links will also make persistent efforts to provide customers with better clinical trial services and create more brilliant results!
LINKS CRO
As a CRO company providing clinical trial services. LINKS CRO focus on innovation, high-risk implantation(intervention) medical device, with one-stop clinical trial solutions for the whole process of medical device research and development.The headquarters of LINKS is based in Shanghai, with subsidiary branches in Beijing, Shanghai, Guangzhou, and Shenzhen, in addition to ten regional offices. The current workforce comprises almost 200 employees, with technical personnel making up over 85% and dispersed across almost 30 cities nationwide.
Key Services include CRO, SMO, CER, Audit, Post-market research, core laboratory registration both domestically and overseas, innovation declaration, Expert Consultancy, and overseas enterprise agency services.
Key Indications include Cardiovascular, Neurovascular, Peripheral Vascular, Surgery Robot, Oncology, Ophthalmology, Medical Cosmetology, and other fields such as orthopedics. There are almost 300 projects consultations and services by LINKS each year.
